PBIRx

09/11/2026

Twenty-five years ago today, we faced one of the darkest days in our nation’s history, an attack that claimed nearly 3,000 innocent lives - men, women, and children - and forever changed us.
We remember those we lost.
We pay tribute to the families who continue to carry their legacy.
We honor the courage of survivors and first responders.
We recall our collective strength, resilience, and unity as Americans.
We

09/04/2026

PBIRx is proud to support the Service CU Impact Foundation’s annual Golf Charity Classic - directly supporting and by providing life-changing mobility devices, support dogs, wellness programs, everyday essentials and more.

09/03/2026

Today's headline AGAIN? "Employer Health Costs Are Expected to Spike in 2027." And these headlines are shifting from forecast to reality. Are you shifting your pharmacy benefit strategy in time to stem the tide?

THIS CHALLENGE IS EXACTLY WHAT WAS BUILT FOR.

Employer health costs are projected to rise 11% next year unless benefits are cut, the highest rate in decades. And even after employers make changes, costs are still expected to climb about 8%, the steepest since 2003.

And zoom out: healthcare costs could see a climb of 76% in just the last decade. Some employers are already responding by dropping

GLP-1 coverage or cutting spousal eligibility just to keep the number manageable.

Specialty and GLP-1 drugs are among the biggest cost drivers behind these projections, and that's the piece of the plan most employers have the least visibility into.

As the premier pharmacy benefit consulting and auditing firm, PBIRx helps you find where the real spend is hiding, negotiate smarter contracts, and design a strategy that protects your plan and your people. Leverage our 30+ years of highly specialized industry knowledge before renewal season hits.

Read article here: https://www.nytimes.com/2026/09/02/business/health-insurance-increases.html

09/01/2026

Price tags that would once have been considered unthinkable are now routine for . A newly FDA approved pancreatic pill has a monthly list price of $39,800 a month. is predicted to be a blockbuster with the potential to become one of the world’s best-selling drugs.
THESE HIGH-PRICED SPECIALTY DRUGS ARE NO LONGER OUTLIER: A cutting-edge CAR-T therapy - $600,000 for a one-time infusion; a competitor: $550,000. A daily pill for gastrointestinal cancer - $520,000 a year. A twice-daily pill for leukemia - $430,000 a year.
The part that should worry every plan sponsor? One employee with an unfortunate diagnosis can blow up an entire benefit plan's budget for the year, and there's rarely warning before it happens.
PBIRx helps clients navigate growing specialty drug spend while ensuring members receive high-quality, appropriate care. We help employers see these costs coming, build stop-loss and specialty drug strategies, and make sure a single high-cost claim does not undo years of careful plan design.
If your plan does not have a clear answer for "what happens when a $480,000 drug claim hits," let's talk.

Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.

08/26/2026

BREAKING: approves first-in-class drug. For patients with one of the deadliest cancers, the oral medication could double survival time. PBIRx helps clients navigate growing specialty drug spend while ensuring members receive high-quality, appropriate care.

LOOK AHEAD: drug spend in the US tops $99 billion annually according to the US National Institutes of Health (NIH) – with projections of $180 billion by 2028. While Rasonque does not yet have a list price, the spend pie is changing. Cancer therapies are taking an increasingly larger slice creating new challenges for pharmacy benefit management – making working alongside a consultant never been more critical.

Read here:

The drug is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.

08/25/2026

Get To Know PBIRx's CTIRx Division – The Clinical Team Monitoring Your Drug Spend!
Behind every recommendation from PBIRx is a team that goes far beyond claims data. PBIRx's dedicated division, CTIRx® – Clinical Technology Intelligence – ensures you are always informed and equipped to make the most strategic pharmacy benefit decisions.

Our team of PharmDs and Clinical Pharmacy Consultants provide timely reporting and recommendations. These customized solutions are designed to enhance plan performance, manage emerging trends, and provide valuable guidance on formulary design.

The result? Proactive plan designs and clinical recommendations built on experience and deep knowledge of the ever-changing pharmacy benefit landscape.

With specialty and GLP-1 drug costs driving plan spend and reshaping benefit budgets, having pharmacists and clinical experts actively watching utilization is not a subset of plan management, it's the difference between REACTING to spend and GETTING AHEAD of it.

PBIRx Clinical Consulting Team in Action
• Reduce unnecessary pharmacy spend by identifying and eliminating waste
• Insulate plan from adverse drug cost and utilization trends
• Align therapy utilization with evidence-based best practices
• Ensure appropriate access to optimal drug therapy for members
• Mitigate future cost trends through proactive management

Learn more about PBIRx’s CTIRx division – Clinical Technology Intelligence at: pbirx.com/clinical-technology-intelligence/

07/01/2026

PBIRx is proud to announce that Patricia Sirowich has been named to The Hartford Business Journal Power 25 Healthcare list, which identifies leaders who have had a significant impact on the industry and public health. Read our latest press release here: https://pbirx.com/2026/07/01/pbirx-sirowich-named-to-hartford-business-journal-power-25-in-healthcare/

06/04/2026

Today! Still time to join our PBIRx Webinar: : The New Savings Frontier. Explore the Biosimilar market landscape, regulatory influences, PBM vendor strategies and challenges. Register here: https://zoom.us/webinar/register/WN_wzx5TEf4TfWpJwVPdhL5QA #/registration

06/03/2026

PBIRx Executive VP, David Sirowich, sharing more than 30 years of pharmacy benefit expertise and insights as a featured panelist on the future of Rx at the MA 2026

06/02/2026

Join our PBIRx Webinar - : The New Savings Frontier. This webinar will explore the Biosimilar market landscape, regulatory influences, PBM vendor strategies and challenges. Register here: https://zoom.us/webinar/register/WN_wzx5TEf4TfWpJwVPdhL5QA #/registration